WO2009016359A1 - Nouvelles formes de déférasirox - Google Patents

Nouvelles formes de déférasirox Download PDF

Info

Publication number
WO2009016359A1
WO2009016359A1 PCT/GB2008/002572 GB2008002572W WO2009016359A1 WO 2009016359 A1 WO2009016359 A1 WO 2009016359A1 GB 2008002572 W GB2008002572 W GB 2008002572W WO 2009016359 A1 WO2009016359 A1 WO 2009016359A1
Authority
WO
WIPO (PCT)
Prior art keywords
deferasirox
amorphous
pharmaceutical formulation
present
polymorphic
Prior art date
Application number
PCT/GB2008/002572
Other languages
English (en)
Inventor
Aleksandar Danilovski
Aleksandra Dumicic
Nada Kosutic Hulita
Ana Kwokal
Ernest Mestrovic
Masa Rajic Linaric
Miroslav Zegarac
Original Assignee
Pliva Hrvatska D.O.O.
Bucks, Teresa Anne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva Hrvatska D.O.O., Bucks, Teresa Anne filed Critical Pliva Hrvatska D.O.O.
Publication of WO2009016359A1 publication Critical patent/WO2009016359A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Definitions

  • the present invention is concerned with new forms of deferasirox, wherein such new forms include: stable anhydrous forms, new polymorphic forms and new amorphous forms, processes for preparing such forms, pharmaceutical compositions containing the same, therapeutic uses thereof, and methods of treatment employing the same.
  • Polymorphism the occurrence of different crystal forms, is a property of some molecules and molecular complexes.
  • a single molecule can give rise to a variety of crystalline forms having distinct crystal structures and physical properties like melting point, x-ray diffraction pattern, infrared absorption fingerprint, and solid state NMR spectrum.
  • Polymorphic forms as referred to herein can include crystalline and amorphous forms as well as solvate and hydrate forms, which can be further characterized as follows: (i) crystalline forms have different arrangements and/or conformations of the molecules in the crystal lattice, (ii) amorphous forms consist of disordered arrangements of molecules that do not possess a distinguishable crystal lattice and (iii) solvates are crystal forms containing either stoichiometric or non-stoichiometric amounts of a solvent. If the incorporated solvent is water, the solvate is commonly known as a hydrate. When a pharmaceutical substance exists in such polymorphic forms, it is said to exhibit polymorphism.
  • X-ray powder diffraction can also be used to support the existence of polymorphs.
  • Other methods including microscopy, thermal analysis (e.g., differential scanning calorimetry, and hot-stage microscopy), and spectroscopy (e.g., infrared [IR], Raman, solid-state nuclear magnetic resonance [ssNMR]) are also helpful to further characterize polymorphic forms.
  • Pharmaceutical substance polymorphic forms can exhibit different chemical, physical and mechanical properties, including aqueous solubility and dissolution rate, hygroscopicity, particle shape, density, flowability, and compactibility, which in turn can affect processing of the pharmaceutical substance and/or manufacturing of the pharmaceutical product.
  • Polymorphs can also exhibit different stabilities.
  • the most stable polymorphic form of a pharmaceutical substance is often chosen during pharmaceutical development based on the minimal potential for conversion to another polymorphic form and on its greater chemical stability.
  • a meta-stable form can alternatively be chosen for various reasons, including bioavailability enhancement.
  • Crystal morphology is dependent upon the manner (i.e., rate and direction) in which the crystal grows.
  • rate and direction There are numerous examples in the chemical and pharmaceutical industries where crystal shape can affect essential processes such as the dissolution rate of chemicals and biological availability of pharmaceuticals, the handling, packaging and storage of crystalline products, milling, grinding, fragmentation, and dusting, density and texture optimization and wax and scale formation in petrochemicals.
  • Crystal morphology also causes preferred orientation of particles in polycrystalline specimens and can result in preferred orientation which can impact crystallographic analysis, such as X-ray powder diffraction (XRPD).
  • XRPD X-ray powder diffraction
  • Deferasirox has the following structure, of Formula I:
  • Deferasirox is an iron chelating compound and is the active ingredient in the commercial product EXJADE for use in the treatment of patients suffering from chronic iron overload due to blood transfusions of greater than twenty units.
  • EXJADE is supplied as a dispersible tablet containing 125 mg, 250 mg and 500 mg of deferasirox per tablet. The tablet is dispersed in a glass of water or other suitable drink, and the resulting suspension is then administered to the patient.
  • U.S. Patent No. 6,596,750 discloses the preparation of deferasirox wherein the compound is crystallized, washed with ethanol and dried. The patent describes the compound that is obtained as colorless crystals with a melting point of 264-265 0 C.
  • Published PCT Appl. No. WO/03053986 also discloses the preparation of deferasirox, wherein the compound was isolated as a solid precipitate from ethanol by the addition of water, and subsequently dried, yielding the solid as a bright yellow powder which upon exposure to the air absorbed moisture and became lighter in color.
  • Steinhauser et. ai discloses the mode of action by which deferasirox functions as an iron chelator and methods to prepare deferasirox.
  • the resulting crystals, on exposure to air, are described as forming the monohydrate, demonstrating the hygroscopicity of the compound.
  • hygroscopic forms of compounds are avoided due to potential instability such as transformation to pseudo- polymorphic forms, which induce assay variability.
  • hygroscopic forms inherently cause difficulties during manufacturing. These substances require special, low-humidity conditions to preserve their original characteristics.
  • manufacturing equipment such as adhesion to the walls of blenders or tablet presses, as well as potential sticking or laminating of the tablets during compression. Consequently, there is a risk that a final product containing a hygroscopic active compound would lack the desired stability and quality for pharmaceutical manufacture.
  • tablets containing hygroscopic materials require special packaging material and storage conditions to prevent additional absorption of moisture and to preserve desired characteristics of the dosage forms.
  • the present invention is directed to an anhydrous form of deferasirox that is not hygroscopic and is stable in pharmaceutical formulations including formulations that contain a significant amount of excipients that are themselves hygroscopic.
  • the present invention is also directed to further polymorphic forms of deferasirox which are not hygroscopic and are stable in pharmaceutical formulations including formulations that contain a significant amount of excipients that are themselves hygroscopic.
  • the present invention is also directed to an amorphous form of deferasirox.
  • the amorphous form of deferasirox is also not hygroscopic and is stable in pharmaceutical formulations including formulations that contain a significant amount of excipients that are themselves hygroscopic.
  • Amorphous forms are characterized as having a higher energy state than their crystalline counterparts, and as being thermodynamically metastable.
  • they offer several physical properties that have possible advantages such as a higher degree of viscoelasticity (which can aid processability) and a larger degree of molecular mobility (which can translate through to a different behavior, such as increased dissolution, solubility and bioavailability).
  • amorphous forms are conversely sometimes not suitable materials for pharmaceuticals due to their thermodynamic instability which can lead to a spontaneous change to the crystalline state at any point during any process step that introduces energy into the amorphous solid, such as during formulation and storage, particularly at elevated temperatures.
  • a first aspect of the present invention is directed to pharmaceutical formulations comprising: a therapeutically effective amount of a stable anhydrous form of deferasirox; and a pharmaceutically acceptable excipient, wherein said deferasirox is substantially free of its acid addition salts.
  • the present invention is further directed to processes to prepare the stable anhydrous form, processes to prepare the pharmaceutical formulations and methods of using the formulations to treat conditions in a subject in need thereof.
  • the stable anhydrous form of deferasirox is not hygroscopic and in some embodiments the stable anhydrous form of deferasirox is deferasirox Form I.
  • the pharmaceutically acceptable excipient is selected from the group consisting of: a carrier, a diluent, a binder, a disintegrant and combinations thereof and in some further embodiments of the pharmaceutical formulation at least one pharmaceutically acceptable excipient is hygroscopic.
  • deferasirox increases in mass by less than about 0.2% when stored at about 25°C for about 24 hours and at about 80% relative humidity.
  • the formulation is a water-dispersible tablet.
  • the present invention is also directed to a powder, comprising a stable anhydrous form of deferasirox, substantially free of other forms of deferasirox.
  • the stable anhydrous form of deferasirox is substantially free of deferasirox acid addition salts.
  • the stable anhydrous form of deferasirox is substantially free of other forms of deferasirox, and especially is substantially free of deferasirox monohydrate.
  • the powder consists essentially of deferasirox Form I.
  • the deferasirox Form I has at least one peak selected from the group consisting of: 1681 ⁇ 2, 1608 ⁇ 2, 1352 ⁇ 2, 1279 ⁇ 2 and 753 ⁇ 2 wavelength/cm "1 as measured using mid-infrared Fourier transform spectroscopy.
  • the present invention is further directed to a pharmaceutical formulation comprising: a therapeutically effective dose of deferasirox Form I, according to the invention, and a pharmaceutically acceptable excipient, wherein deferasirox is substantially free of its acid addition salts.
  • deferasirox Form I according to the invention, is present in a composition having less than about 5% of any other form of deferasirox.
  • the present invention is also directed to deferasirox Form I, according to the invention for use in therapy.
  • the present invention is also directed to a method of treating a disease prevented, ameliorated or eliminated by the administration of an iron chelating agent, in a subject in need thereof, the method comprising administering to the subject the above mentioned pharmaceutical formulation.
  • the present invention is further directed to a method of treating iron overload following blood transfusion in a subject in need thereof, the method comprising administering to the subject the above mentioned pharmaceutical formulation.
  • deferasirox according to the invention has a mean particle size of about 0.5 ⁇ m to about lO ⁇ m
  • in some embodiments of the pharmaceutical formulation deferasirox, according to the invention has a D [90] of about 10 ⁇ m or less.
  • the pharmaceutical formulation of deferasirox Form I is further characterized by a melting point onset at about 260 ⁇ l°C as determined by differential scanning calorimetry.
  • the present invention is further directed to a suspension of particles of stable anhydrous deferasirox, wherein the deferasirox is substantially free of its acid addition salts and wherein the deferasirox has a mean particle size of about 0.5 ⁇ m to about lO ⁇ m, in water or other drink suitable for human consumption.
  • the present invention is further directed to a method of treating a disease prevented, ameliorated or eliminated by the administration of an iron chelating agent, in a subject in need thereof, the method comprising administering to the subject said suspension.
  • the present invention is also directed to a method of treating iron overload following blood transfusion in a subject in need thereof, the method comprising administering to the subject said suspension.
  • the present invention is also directed to new polymorphic forms of deferasirox.
  • the polymorphic forms of deferasirox are not hygroscopic and are stable in pharmaceutical formulations including formulations that contain a significant amount of excipients that are themselves hygroscopic.
  • the polymorphic forms of deferasirox provided by the present invention are hereinafter referred to as Form II, Form III, Form IV and form V
  • Polymorphic form II of deferasirox characterized as having one or more X-ray powder diffraction peaks selected from the following (2 ⁇ ): 6.5° ⁇ 0.2°, 7.4° ⁇ 0.2°, 10.8° ⁇ 0.2°, 13.4° ⁇ 0.2°, 14.8° ⁇ 0.2°, 19.2° ⁇ 0.2°, 21.7° ⁇ 0.2° and 26.0° ⁇ 0.2°.
  • Polymorphic form II of deferasirox characterized as having one or more X-ray powder diffraction peaks selected from the following (2 ⁇ ): 18.1° ⁇ 0.2°, 19.7° ⁇ 0.2°, 23.4° ⁇ 0.2°, and 24.6° ⁇ 0.2°.
  • Polymorphic form II of deferasirox characterized as having one or more X-ray powder diffraction peaks selected from following (2 ⁇ ): 6.5° ⁇ 0.2°, 7.4° ⁇ 0.2°, 10.8° ⁇ 0.2°, 13.4° ⁇ 0.2°, 14.8° ⁇ 0.2°, 19.2° ⁇ 0.2°, 21.7° ⁇ 0.2° and 26.0° ⁇ 0.2°, and further characterized as having one or more additional X-ray powder diffraction peaks selected from following (2 ⁇ ): 18.1° ⁇ 0.2°, 19.7° ⁇ 0.2°, 23.4° ⁇ 0.2°, 24.6° ⁇ 0.2°.
  • Polymorphic form II of deferasirox characterized as having an X-ray powder diffraction pattern substantially as shown in FIG. 4.
  • Polymorphic form II of deferasirox characterized as having a melting point observed by DSC analysis, at 228 °C ⁇ 1 °C.
  • Polymorphic form II of deferasirox characterized as having an IR spectrum substantially as shown in FIG. 5.
  • Polymorphic form III of deferasirox characterized as having either one or both of the following characteristic X-ray powder diffraction peaks (2 ⁇ ): 12.5° ⁇ 0.2° or 15.7° ⁇ 0.2°.
  • Polymorphic form III of deferasirox characterized as having an X-ray powder diffraction pattern substantially as shown in FIG. 6.
  • Polymorphic form IV of deferasirox characterized as having one or more characteristic X-ray powder diffraction peaks selected from the following (2 ⁇ ): 10.4° ⁇ 0.2°, 11.9° ⁇ 0.2°, 15.0° ⁇ 0.2°, 16.0° ⁇ 0.2°, 21.6° ⁇ 0.2°, and 22.0° ⁇ 0.2°.
  • Polymorphic form IV of deferasirox characterized as having an X-ray powder diffraction pattern substantially as shown in FIG. 7.
  • Polymorphic form IV of deferasirox characterized as having a melting point peak observed, by DSC analysis, at 202 °C ⁇ 1 0 C.
  • Polymorphic form V of deferasirox characterized as having one or more characteristic X-ray powder diffraction peaks selected from the following (2 ⁇ ): 5.5° ⁇ 0.2°, 11.0° ⁇ 0.2°, 11.8° ⁇ 0.2°.
  • the present invention also provides a process of preparing polymorphic forms
  • deferasirox comprising alternately melting and cooling deferasirox in one or more cycles and in an inert atmosphere. Cooling of melted deferasirox is carried out down to room temperature under controlled conditions with cooling rate from 10 to 50 °C/min, preferably 20 to 40 °C/min.
  • the preferred inert atmosphere is nitrogen.
  • the present invention also provides a process of preparing polymorphic form rv of deferasirox comprising crystallization from ethanol solution of deferasirox with use of sulfuric acid.
  • the present invention also provides a process of preparing polymorphic form
  • V of deferasirox comprising sublimation of deferasirox.
  • Deferasirox is an iron chelating compound, and is thus useful in the treatment of disorders in patients suffering from elevated levels of iron.
  • a pharmaceutical formulation comprising: (a) a therapeutically effective amount of deferasirox form II, form III, form IV, form V or a mixture thereof, according to the invention, and (b) a pharmaceutically acceptable excipient. Excipients are chosen according to the pharmaceutical form and the desired mode of administration.
  • a pharmaceutical formulation of the present invention wherein the pharmaceutically acceptable excipient is selected from the group consisting of: a carrier, a diluent, a binder, a disintegrant and combinations thereof.
  • a water dispersible tablet of the present invention wherein the dispersible tablet disintegrates in about 3 minutes in about 1 1 of water at about 15 °C to about 25 °C.
  • a pharmaceutical formulation of the present invention wherein deferasirox form II or form III or form IV or form V or a mixture thereof, has a mean particle size of about 0.5 ⁇ m to about lO ⁇ m.
  • the present invention also provides a pharmaceutical formulation, wherein the deferasirox form II or form III or form IV or form V or a mixture thereof, has a D [90] of about 10 ⁇ m or less.
  • the present invention also provides a method of treating a disease prevented, ameliorated or eliminated by the administration of an iron chelating agent in a subject in need thereof, comprising administering to the subject the pharmaceutical formulation described above.
  • V or a mixture thereof has a mean particle size of about 0.5 ⁇ m to about lO ⁇ m, in water or other drink suitable for human consumption.
  • a method of treating a disease prevented, ameliorated or eliminated by the administration of an iron chelating agent in a subject in need thereof, comprising administering to the subject the suspension described above.
  • deferasirox may form several different amorphous forms with different physical properties.
  • Amorphous form I of deferasirox characterized as having a peak crystallization point, as measured by differential scanning calorimetry, of 159.0°C ⁇ 1°C, ideally ⁇ 0.5°C.
  • Amorphous form I of deferasirox characterized as having an onset of the crystallization point, as measured by differential scanning calorimetry, of 144.6°C ⁇ 1°C, ideally ⁇ 0.5°C.
  • Amorphous form I of deferasirox characterized as having an X-ray diffraction pattern substantially as shown in Figure 10.
  • Amorphous form II of deferasirox characterized as having a peak crystallization point, as measured by differential scanning calorimetry, of 153.6° C ⁇ 1°C, ideally ⁇ 0.5°C.
  • Amorphous form II of deferasirox characterized as having an onset of the crystallization point, as measured by differential scanning calorimetry, of 143.5°C ⁇ rC, ideally ⁇ 0.5°C.
  • Amorphous form II of deferasirox characterized as having an X-ray diffraction pattern substantially as shown in Figure 12.
  • Amorphous form III of deferasirox characterized as having no crystallization point, as measured by differential scanning calorimetry, at any point up to 350°C.
  • Amorphous form III of deferasirox characterized as having an X-ray diffraction pattern substantially as shown in Figure 14.
  • Amorphous form IV of deferasirox characterized as having a peak crystallization point, as measured by differential scanning calorimetry, of 96.5 °C ⁇ rC, ideally ⁇ 0.5°C.
  • Amorphous form IV of deferasirox characterized as having an onset of the crystallization point, as measured by differential scanning calorimetry, of 87.7°C ⁇ 1°C, ideally ⁇ 0.5°C.
  • Amorphous form IV of deferasirox characterized as having an X-ray diffraction pattern substantially as shown in Figure 16.
  • Amorphous form I of deferasirox characterized as having an FTIR spectra substantially as shown in Figure 18 or 19.
  • Amorphous form II of deferasirox characterized as having an FTIR spectra substantially as shown in Figure 18 or 19.
  • Amorphous form III of deferasirox characterized as having an FTIR spectra substantially as shown in Figure 18 or 19.
  • Amorphous form IV of deferasirox characterized as having an FTIR spectra substantially as shown in Figure 18 or 19.
  • the amorphous forms of deferasirox are preferably substantially free of its acid addition salts.
  • the phrase "substantially free of its acid addition salts" refers to amorphous deferasirox free of salts formed by addition with an acid, such acids include but are not limited to; hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, ethanesulphonic acid, toluenesulphonic acid, benzenesulphonic acid, naphthalenedisulphonic acid, acetic acid, propionic acid, oxalic acid, lactic acid, tartaric acid, citric acid, fumaric acid, maleic acid and benzoic acid.
  • the present invention also provides a process of preparing amorphous deferasirox comprising melting a sample of deferasirox and then cooling to 20 °C. Ideally the cooling step should take less than five minutes, ideally less than one minute.
  • a pharmaceutical formulation comprising: a therapeutically effective amount of an amorphous deferasirox; according to the invention, and a pharmaceutically acceptable excipient.
  • the present invention also provides a pharmaceutical formulation, wherein the therapeutically effective amount of amorphous deferasirox is selected from the group consisting of: amorphous deferasirox form I, amorphous deferasirox form II, amorphous deferasirox form III, amorphous form deferasirox IV and combinations thereof.
  • the pharmaceutically acceptable excipient is selected from the group consisting of: a carrier, a diluent, a binder, a disintegrant and combinations thereof.
  • the present invention also provides a water dispersible tablet, wherein the dispersible tablet disintegrates in about 3 minutes in about 1 1 of water at about 15 °C to about 25 °C.
  • the present invention also provides a powder, comprising an amorphous form of deferasirox selected from the group comprising of amorphous form I, amorphous form II, amorphous form III and amorphous form IV or any combination thereof.
  • the present invention also provides a pharmaceutical formulation, wherein the amorphous deferasirox has a mean particle size of about 0.5 ⁇ m to about lO ⁇ m.
  • amorphous deferasirox has a D[90] of about 10 ⁇ m or less.
  • the present invention provides a method of treating a disease prevented, ameliorated or eliminated by the administration of an iron chelating agent, in a subject in need thereof, the method comprising administering to the subject the pharmaceutical formulation of the invention.
  • the present invention also provides a method of treating iron overload following blood transfusion in a subject in need thereof, the method comprising administering to the subject the pharmaceutical formulation of the invention.
  • the present invention provides a method of treating a disease prevented, ameliorated or eliminated by the administration of an iron chelating agent, in a subject in need thereof, the method comprising administering to the subject the suspension as described above.
  • the present invention also provides a method of treating iron overload following blood transfusion in a subject in need thereof, the method comprising administering to the subject the suspension as described above.
  • FIG. 1 depicts an FTNIR spectra of Deferasirox Form I, recorded on a Bruker spectrophotometer (MPA NIR Spectrophotometer) by the solid reflectance probe at a resolution of 8 cm "1 .
  • FIG. 2 depicts a FTMID-IR spectra of Deferasirox Form I, recorded on a
  • FIG. 3 depicts a low angle laser light scattering plot used for particle size determination of Deferasirox Form I.
  • FIG. 4 depicts a X-ray powder diffraction pattern of Deferasirox form II.
  • FIG. 5 depicts an IR spectrum of Deferasirox form II.
  • FIG. 6 depicts an X-ray powder diffraction pattern of Deferasirox form III.
  • FIG. 7 depicts an X-ray powder diffraction pattern of Deferasirox form IV.
  • FIG. 8 depicts an IR spectrum of Deferasirox form IV.
  • FIG. 9 depicts a DSC thermogram of amorphous form I of Deferasirox.
  • FIG. 10 depicts an XRPD of amorphous form I of Deferasirox.
  • FIG. 11 depicts a DSC thermogram of amorphous form II of Deferasirox.
  • FIG. 12 depicts an XRPD of deferasirox amorphous form II of Deferasirox.
  • FIG. 13 depicts a DSC thermogram of Deferasirox amorphous form III of
  • FIG. 14 depicts a XRPD of Deferasirox amorphous form III of Deferasirox.
  • FIG. 15 depicts a DSC thermogram of Deferasirox amorphous form IV of
  • FIG. 16 depicts a XRPD of Deferasirox amorphous form IV of Deferasirox.
  • FIG. 17 depicts a comparison of the XRPD spectra of amorphous forms I, II, II and IV of Deferasirox.
  • FIG. 18 depicts a comparison of the FTIR spectra of amorphous forms I, II, III and IV of Deferasirox between the wavenumber 1800 and 1200 cm "1 .
  • FIG. 19 depicts a comparison of the FTIR spectra of amorphous forms I, II, III and rv of Deferasirox between the wavenumber 1220 and 400 cm " .
  • One aspect of the present invention is directed to a pharmaceutical formulation comprising a therapeutically effective amount of a stable anhydrous form of deferasirox; and a pharmaceutically acceptable excipient, wherein said deferasirox is substantially free of its acid addition salts.
  • the present invention is further directed to processes to prepare the stable form, processes to prepare the pharmaceutical formulations and methods of using the formulations to treat conditions in a subject in need thereof.
  • Deferasirox 4-(3,5-bis-(hydroxy-phenyl)-l,2,4)triazol-l-yl)benzoic acid, is an iron chelating agent, useful in the treatment of disorders in subjects suffering from elevated levels of iron.
  • the stable anhydrous form of deferasirox is deferasirox
  • the phrase “stable anhydrous” refers to the fact that deferasirox Form I is “not hygroscopic,” nor “slightly hygroscopic,” or even “very hygroscopic” or even “deliquescent.”
  • the terms hygroscopic, slightly hygroscopic, very hygroscopic and deliquescent are defined by reference to the European Pharmacopoeia Technical Guide (1999, page 86) whereby, following storage at 25°C for 24 hours at 80% Relative Humidity (RH), slightly hygroscopic is defined as an increase in mass of less than 2% (w/w - weight per weight) and equal to or greater than 0.2% w/w.
  • Hygroscopic is defined as an increase in mass of less than 15% (w/w) and equal to or greater than 0.2% (w/w). Very hygroscopic is defined as an increase in mass of equal to or greater than 15% (w/w), whilst deliquescent is defined as a sufficient amount of water absorbed to form a liquid.
  • anhydrous deferasirox increases in mass less than about 0.2% when stored at about 25 0 C for about 24 hours at about 80% relative humidity.
  • substantially free of its acid addition salts refers to deferasirox free of salts formed by addition with an acid, such acids include but are not limited to; hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, ethanesulphonic acid, toluenesulphonic acid, benzenesulphonic acid, naphthalenedisulphonic acid, acetic acid, propionic acid, oxalic acid, lactic acid, tartaric acid, citric acid, fumaric acid, maleic acid and benzoic acid.
  • hydrochloric acid hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, ethanesulphonic acid, toluenesulphonic acid, benzenesulphonic acid, naphthalenedisulphonic acid, acetic acid, propionic acid, oxalic acid, lactic acid, tartaric acid, citric acid, fumaric acid
  • the formulation is in the form of a dispersible tablet, in some embodiments the pharmaceutical formulation is a water-dispersible tablet. It is preferable for the performance of the dispersible tablet that the at least one of the carrier, diluent or any other excipient is hygroscopic so to accelerate water intake providing rapid dispersion of the tablet. Therefore, a further advantage is that the stable anhydrous form of the present invention is particularly suitable for use in water- dispersible tablets that contain hygroscopic excipients as there will be no potential instability of the pharmaceutical substance and numerous difficulties during manufacturing stated above will be avoided.
  • deferasirox Form I can optionally be used as a pharmaceutical formulation in the form of a powder, or in the form of granules.
  • Controlling the particle size of the deferasirox, according the present invention enhances bioavailability and control during the manufacturing process. Therefore for particle size within a specified narrow range, pharmaceutical formulations may be prepared which exhibit both a consistent in vitro dissolution profile and in vivo bioavailability, hi addition to bringing about these desired dissolution/bioavailability characteristics, the control of particle size to a narrow range has also resulted in significant improvements in manufacturing capabilities.
  • the particle size measurements of the deferasirox are mean particle size, which means the value D[4,3], the volume moment mean of the particles, D [90], the diameter of which 90% by weight of the particles are smaller than and D[50], the diameter of which 50% by weight of the particles are smaller than. All measurements are made by low angle laser light scattering (LALLS) as determined typically by a Malvem Mastersizer machine.
  • LALLS low angle laser light scattering
  • the present invention is also directed to a powder, comprising a stable anhydrous form of deferasirox, substantially free of other forms of deferasirox.
  • the stable anhydrous form of deferasirox is substantially free of deferasirox hydrochloride salt and in some embodiments the powder consisting essentially of deferasirox Form I, free of any other form of deferasirox and in some embodiments of the powder deferasirox Form I has at least one peak selected from the group consisting of: 1681 ⁇ 2, 1608 ⁇ 2, 1352 ⁇ 2, 1279 ⁇ 2 and 753 ⁇ 2 wavelength/cm '1 can be measured using mid-infrared Fourier transform spectroscopy.
  • the pharmaceutical formulation of the present invention comprises a therapeutically effective dose of deferasirox Form I, according to the present invention, and a pharmaceutically acceptable excipient, wherein deferasirox is substantially free of its acid addition salts.
  • Form I is present in a composition having less than about 10% to about 5% of any other form of deferasirox, in some embodiments of the pharmaceutical formulation deferasirox, according to the present invention, is present in a composition having less than about 5% to about 1% of any other form of deferasirox and in some embodiments of the pharmaceutical formulation deferasirox, according to the present invention, is present in a composition having less than about 1% to about 0.1% of any other form of deferasirox.
  • the deferasirox Form I, according to the present invention, of the pharmaceutical formulation has a mean particle size of about 0.1 ⁇ m to about 50 ⁇ m, in some embodiments of the current invention the deferasirox, according to the present invention, of the pharmaceutical formulation has a mean particle size of about 0.5 ⁇ m to about 25 ⁇ m and in some embodiments of the current invention the deferasirox, according to the present invention, of the pharmaceutical formulation has a mean particle size of about l ⁇ m to about lO ⁇ m.
  • the deferasirox Form I, according to the present invention, of the pharmaceutical formulation has a D [90] of about 50 ⁇ m or less, in some embodiments of the current invention the deferasirox, according to the present invention, of the pharmaceutical formulation has a D [90] of about 25 ⁇ m and in some embodiments of the current invention the deferasirox, according to the present invention, of the pharmaceutical formulation has a D [90] of about 10 ⁇ m or less.
  • the deferasirox Form I, according to the present invention, of the pharmaceutical formulation has a D [50] of about 25 ⁇ m or less, in some embodiments of the current invention the deferasirox, according to the present invention, of the pharmaceutical formulation has a D [50] of about lO ⁇ m and in some embodiments of the current invention the deferasirox, according to the present invention, of the pharmaceutical formulation has a D [50] of about 5 ⁇ m or less.
  • the deferasirox Form I, according to the present invention, of the pharmaceutical formulation has a mean particle size of about 50 ⁇ m or less, in some embodiments of the current invention the deferasirox, according to the present invention, of the pharmaceutical formulation has a mean particle size of about 25 ⁇ m and in some embodiments of the current invention the deferasirox, according to the present invention, of the pharmaceutical formulation has a mean particle size of about 10 ⁇ m or less.
  • Some embodiments of the present invention include use of deferasirox Form I, according to the invention, in the manufacture of a medicament that is substantially free of any acid addition salt of deferasirox, for the treatment of a disease prevented, ameliorated or eliminated by the administration of an iron chelating agent.
  • Another embodiment of the present invention is use of deferasirox, according to the invention, in the manufacture of a medicament that is substantially free of any acid addition salt of deferasirox, for a treatment of iron overload following blood transfusion.
  • Some embodiments of the present invention include a method of treating a disease prevented, ameliorated or eliminated by the administration of an iron chelating agent, in a subject in need thereof, the method comprising administering to the subject a pharmaceutical formulation, according to the invention.
  • the method comprising administering to the subject pharmaceutical formulation, according to the invention.
  • Further embodiments include a method of treating a disease prevented, ameliorated or eliminated by the administration of an iron chelating agent, in a subject in need thereof, the method comprising administering to the subject a suspension formed by the addition of the pharmaceutical formulation of the present invention in water or other suitable drink suitable for human consumption, and in some embodiments a method of treating iron overload following blood transfusion in a subject in need thereof, the method comprising administering to the subject the suspension of said formulation.
  • Deferasirox Form I has at least one characterising peak selected from; 1681 ⁇ 2,
  • Deferasirox Form I has at least one characterising 2 ⁇ peak selected from;
  • the present invention is also directed to a process for preparing deferasirox
  • Form I comprising: dissolving deferasirox, or a salt thereof, in any suitable solvent and precipitation with the use of a suitable anti-solvent.
  • a second example provides a process of preparing deferasirox Form I comprising; dissolving deferasirox, or a salt thereof, in any suitable solvent and crystallization by cooling or seeding with crystals of deferasirox Form I.
  • the present invention also provides a process of preparing deferasirox Form I comprising dissolving deferasirox in solvent (or mixture of solvents)/base system and precipitation with the use of solvent (or mixture of solvents)/acid system.
  • the present invention also provides a process of preparing deferasirox Form I comprising dissolving deferasirox in solvent (or mixture of solvents)/acid system and precipitation with the use of solvent (or mixture of solvents)/base system.
  • a suitable solvent can be selected from the group comprising; ethanol, acetone, acetonitrile, 1-butanol, 2-butanol, butyl-acetate, N,N-dimethylacetamide, N,N-dimethylformamide, dimethylsulfoxide, 1,4-dioxane, ethyl-acetate, methanol, methyl-acetate, 2-hexanone, 2-butanone, methyl-isobutyl ketone, 1-propanol, 2- propanol, propyl-acetate, tetrahydrofurane and combinations thereof and the water mixtures of any single solvent or water mixtures of any combination of solvents thereof.
  • a suitable anti-solvent is selected from the group comprising water, pentane, hexane, heptane, octane, decane, ethyl ether, methyl-tert-butyl ether, diisopropyl ether and any combinations thereof.
  • a suitable base is selected from following: sodium hydroxide, calcium hydroxide, magnesium hydroxide, potassium hydroxide and sodium hydrogen carbonate.
  • Suitable acid is selected from following: hydrochloric acid, hydrobromic acid, benzenesulfonic acid, camphorsulfonic acid, ethanesulfonic acid, fumaric acid, phthalic acid, maleic acid, methanesulfonic acid, oxalic acid, phosphoric acid, salicylic acid and sulfuric acid.
  • the process of producing deferasirox Form I in some embodiments can also include additional steps, comprising heating or cooling during either dissolution or precipitation, filtration, evaporation and washing of crystals, drying and any combination thereof.
  • Granulate deferasirox with an aqueous dispersion of crospovidone and sodium lauryl sulfate Screen the dried granules through a 30 mesh (0.6 mm) sieve, and add all of the other substances, except magnesium stearate, and homogenize for 15 minutes. Add magnesium stearate, previously screened through a 30 mesh (0.6 mm) sieve, to the final blend and homogenize for another 5 minutes. The final blend is compressed into tablets.
  • FTNIR reflectance spectra of deferasirox Form I was recorded with 32 scans on a Bruker spectrophotometer (MPA NIR Spectrophotometer) by the solid reflectance probe and at a resolution 8 cm "1 , an FTMID-IR spectrum was recorded on a Perkin Elmer spectrophotometer (Spectrum GX) in a KBr pellet at a resolution of 4 cm "1 as depicted in FIG. 2.
  • LALLS Low angle laser light scattering
  • was used was used to determine particle size range, the instrument used was a Malvern 2000 with Hydro 2000 ⁇ P unit. The goodness of fit were determined by a weighted residual which accounted less than 1%. Relative standard deviation between measurements were less than 15% for D(0.9) and less than 10% for D(0.1) and D(0.5).
  • the present invention is also directed to new polymorphic forms of deferasirox.
  • the present invention is also directed to pharmaceutical formulations thereof, processes to prepare the stable forms and the pharmaceutical formulations and methods of using the formulations.
  • polymorphic form II of deferasirox is characterized as having one or more characteristic X-ray powder diffraction peaks selected from following (2 ⁇ ): 6.5° ⁇ 0.2°, 7.4° ⁇ 0.2°, 10.8° ⁇ 0.2°, 13.4° ⁇ 0.2°, 14.8° ⁇ 0.2°, 19.2° ⁇ 0.2°, 21.7° ⁇ 0.2° and 26.0° ⁇ 0.2°.
  • polymorphic form II of deferasirox is characterized as having one or more characteristic X-ray powder diffraction peaks selected from following 18.r ⁇ 0.2°, 19.7° ⁇ 0.2°, 23.4° ⁇ 0.2°, 24.6° ⁇ 0.2°.
  • polymorphic form II of deferasirox is characterized as having one or more characteristic X-ray powder diffraction peaks selected from following (2 ⁇ ): 6.5° ⁇ 0.2°, 7.4° ⁇ 0.2°, 10.8° ⁇ 0.2°, 13.4° ⁇ 0.2°, 14.8° ⁇ 0.2°, 19.2° ⁇ 0.2°, 21.7° ⁇ 0.2° and 26.0° ⁇ 0.2°, and further characterized as having one or more additional X-ray powder diffraction peaks selected from following (2 ⁇ ): 18.1° ⁇ 0.2°, 19.7° ⁇ 0.2°, 23.4° ⁇ 0.2°, 24.6° ⁇ 0.2°.
  • polymorphic form II of deferasirox is characterized as having an X-ray powder diffraction pattern substantially as shown in FIG 4.
  • polymorphic form II of deferasirox is characterized as having a melting point observed, by DSC analysis, at 228 °C ⁇ 1 °C.
  • polymorphic form II of deferasirox is characterized as having an IR spectrum substantially as shown in FIG 5.
  • polymorphic form III of deferasirox is characterized as having either one or both of the following characteristic X-ray powder diffraction peaks selected from following (2 ⁇ ): 12.5° ⁇ 0.2° or 15.7° ⁇ 0.2°.
  • polymorphic form III of deferasirox characterized as having an X-ray powder diffraction pattern substantially as shown in FIG 6.
  • polymorphic form III of deferasirox is characterized as having a melting point observed, by DSC analysis, at 208 0 C ⁇ 1 0 C.
  • polymorphic form IV of deferasirox is characterized as having one or more characteristic X-ray powder diffraction peaks selected from following (2 ⁇ ): 10.4° ⁇ 0.2°, 11.9 o ⁇ 0.2°, 15.0° ⁇ 0.2°, 16.0° ⁇ 0.2°, 21.6° ⁇ 0.2°, and 22.0° ⁇ 0.2°.
  • polymorphic form IV of deferasirox is characterized as having an X-ray powder diffraction pattern substantially as shown in FIG 7.
  • polymorphic form FV of deferasirox is characterized as having an IR spectrum substantially as shown in FIG 8.
  • polymorphic form IV of deferasirox is characterized as having a melting point observed, by DSC analysis, at 202 °C ⁇ 1 °C.
  • the present invention also provides a process of preparing polymorphic forms
  • deferasirox comprising alternately melting and cooling of deferasirox in one or more cycles and in an inert atmosphere.
  • Melted deferasirox is cooled to room temperature under controlled conditions with a cooling rate from about 10 °C/min to about 50 °C/min, preferably 20 °C/min to 40 °C/min. Cooling is preferably carried out in an inert atmosphere of nitrogen.
  • the present invention also provides a process of preparing polymorphic form rV of deferasirox comprising crystallization from ethanol and sulfuric acid.
  • the present invention is directed to a pharmaceutical formulation comprising: (a) a therapeutically effective amount of deferasirox form II or form III or form IV or form V or a mixture thereof, according to the invention, and (b) a pharmaceutically acceptable excipient.
  • the formulation is in the form of a dispersible tablet, in some embodiments the pharmaceutical formulation is a water-dispersible tablet, in a further embodiment, the water dispersible tablet of the present invention disintegrates in about 3 minutes in about 1 1 of water at about 15 0 C to about 25 °C.
  • the present invention is directed to a powder comprising deferasirox form II, form III, form IV or a mixture thereof, according to the invention.
  • deferasirox form II or form III or form IV or form V or a mixture thereof, according to the invention has a mean particle size of about 0.5 ⁇ m to about lO ⁇ m and in some embodiments the deferasirox form II, form III, form IV or a mixture thereof, according to the invention, has a D[90] of about 10 ⁇ m or less.
  • the present invention is directed to a method of treating a disease prevented, ameliorated or eliminated by the administration of an iron chelating agent, in a subject in need thereof, the method comprising administering to the subject the pharmaceutical formulation comprising deferasirox form II, form III, form IV or a mixture thereof, of the present invention.
  • the present invention is directed to a method of treating iron overload following blood transfusion in a subject in need thereof, the method comprising administering to the subject the pharmaceutical formulation of the present invention.
  • the present invention is also directed to a suspension of particles of deferasirox form II or form III or form IV or form V or a mixture thereof, according to the invention, according to the invention, in water or other drink suitable for human consumption wherein the deferasirox form II, form III, form IV or a mixture thereof, according to the invention, has a mean particle size of about 0.5 ⁇ m to about lO ⁇ m.
  • the present invention is further directed to a suspension of particles of deferasirox form II, form III, form IV or a mixture thereof, according to the invention, wherein the deferasirox has a mean particle size of about 0.5 ⁇ m to about lO ⁇ m, in water or other drink suitable for human consumption.
  • the present invention also provides a method of treating a disease prevented, ameliorated or eliminated by the administration of an iron chelating agent, in a subject in need thereof, such method comprises administering to the subject the suspension, according to the invention, hi further embodiments the present invention provides a method of treating iron overload following blood transfusion in a subject in need of such treatment, the method comprising administering to the subject the suspension of the present invention.
  • deferasirox form II 10 mg of deferasirox is placed in open platinum sample pan (volume 50 ⁇ l) under nitrogen stream with a flow rate of 35 ml/min. The sample is equilibrated at 20 0C, heated with heating rate of 10 °C up to 270 °C (melting), isothermal point was held at 270 °C for 1 minute, then cooled with a rate of 30 °C/min down to 20 °C, and then heated with 5 °C/min up to 215 °C to obtain polymorphic form II of deferasirox.
  • deferasirox form IV 50 mg of deferasirox (DEF-05-K) was dissolved in 10 ml of ethanol (96%).
  • Deferasirox form II or form III or form IV or form V is mixed with all the inert substances, except magnesium stearate, and homogenize for 15 minutes.
  • Magnesium stearate, previously screened through a 30 mesh (0.6 mm) sieve is added to the final blend and homogenize for a further 5 minutes.
  • the final blend is compressed into tablets.
  • Example 2F
  • Deferasirox form II or form III or form IV or form V is mixed with all the inert ingredients, except magnesium stearate, and homogenize for 15 minutes.
  • Granulate deferasirox form II or form III or form IV or form V is formed with an aqueous dispersion of crospovidone and sodium lauryl sulfate.
  • the dried granules are screened through a 30 mesh (0.6 mm) sieve, and all of the other inert ingredients, except magnesium stearate, are added and homogenize for 15 minutes.
  • Magnesium stearate, previously screened through a 30 mesh (0.6 mm) sieve, is added to the final blend and homogenize for another 5 minutes. The final blend is compressed into tablets.
  • Another aspect of the present invention relates to amorphous deferasirox.
  • the present invention is also directed to pharmaceutical formulations thereof; processes to prepare the stable form and the pharmaceutical formulations and methods of using the formulations.
  • amorphous forms of deferasirox can be characterized by their crystalization point by diferential scanning calorimetry.
  • the crystalization point is the temperature, as measured by DSC, at which conversion of the amorphous form into a non amorphous form occurs.
  • the greater the thermal stability of the amorphous form then it can be predicted that the amorphous form is less likely to undergo a rearrangement into a crystalline form during a formulation process and during the storage conditions of the formulation.
  • amorphous form I of deferasirox is characterized as having a peak crystallization point, as measured by differential scanning calorimetry, of about 159.0 0 C ⁇ 1°C, ideally +0.5 °C. In some embodiments amorphous form I of deferasirox is characterized as having an onset of the crystallization point, as measured by differential scanning calorimetry, of about 144.6 °C +1 °C, ideally +0.5 0C. In further embodiments amorphous form I of deferasirox is characterized as having an X-ray diffraction pattern substantially as shown in FIG. 10. In some embodiments amorphous form I of deferasirox is further characterized as having an FTIR spectra substantially as shown in FIG. 18 or 19.
  • amorphous form II of deferasirox is characterized as having a peak crystallization point, as measured by differential scanning calorimetry, of 153.6 °C ⁇ 1°C, ideally +0.5 °C. In some embodiments amorphous form II of deferasirox characterized as having an onset of the crystallization point, as measured by differential scanning calorimetry, of 143.5 °C ⁇ 1 °C, ideally ⁇ 0.5 °C. In further embodiment's amorphous form II of deferasirox characterized as having an X-ray diffraction pattern substantially as shown in FIG. 12. In some embodiments, amorphous form II of deferasirox is characterized as having an FTER spectra substantially as shown in FIG. 18 or 19.
  • amorphous form III of deferasirox can be characterized as having no crystallization point, as measured by differential scanning calorimetry, at any point up to 350 °C, also in some embodiments amorphous form III of deferasirox is characterized as having an X-ray diffraction pattern substantially as shown in FIG. 14. In some embodiments of the present invention, amorphous form III of deferasirox is characterized as having an FTIR spectra substantially as shown in FIG. 18 or 19.
  • amorphous form IV of deferasirox is characterized as having a peak crystallization point, as measured by differential scanning calorimetry, of about 96.5 °C ⁇ 1°C, ideally +0.5 °C, in some embodiments amorphous form IV of deferasirox characterized as having an onset of the crystallization point, as measured by differential scanning calorimetry, of about 87.7 °C +1 0 C, ideally +0.5 °C and in further embodiments amorphous form IV of deferasirox can be characterized as having an X-ray powder diffraction pattern substantially as shown in FIG 16, in some embodiments, amorphous form FV of deferasirox is characterized as having an FTIR spectra substantially as shown in FIG. 18 or 19.
  • the present invention also provides a process for preparing an amorphous form of deferasirox, comprising melting a sample of deferasirox and then cooling to 20 0 C. Ideally the cooling step should take less than five minutes, ideally less than one minute
  • the present invention is directed to a pharmaceutical formulation comprising: a therapeutically effective amount of an amorphous deferasirox; according to the invention, and a pharmaceutically acceptable excipient.
  • a further embodiment of the present invention is directed to a pharmaceutical formulation comprising amorphous deferasirox, wherein the amorphous deferasirox is substantially free of its acid addition salts and in some embodiments wherein the therapeutically effective amount of amorphous deferasirox is selected from the group consisting of: amorphous deferasirox form I, amorphous deferasirox form II, amorphous deferasirox form III, amorphous form deferasirox IV and combinations thereof.
  • the formulation is in the form of a dispersible tablet, in some embodiments the pharmaceutical formulation is a water-dispersible tablet, in a further embodiment, the water dispersible tablet of the present invention disintegrates in about 3 minutes in about 1 1 of water at about 15 °C to about 25 °C.
  • the present invention is directed to a powder, comprising an amorphous form of deferasirox selected from the group comprising of amorphous form I, amorphous form II, amorphous form III and amorphous form IV or any combination thereof.
  • amorphous deferasirox has a mean particle size of about 0.5 ⁇ m to about lO ⁇ m and in some embodiments the amorphous deferasirox has a D[90] of about 10 ⁇ m or less.
  • the present invention is directed to a method of treating a disease prevented, ameliorated or eliminated by the administration of an iron chelating agent, in a subject in need thereof, the method comprising administering to the subject the pharmaceutical formulation comprising an amorphous form of deferasirox selected from the group comprising of amorphous form I, amorphous form II, amorphous form III and amorphous form IV or any combination thereof; of the present invention.
  • the present invention is directed to a method of treating iron overload following blood transfusion in a subject in need thereof, the method comprising administering to the subject the pharmaceutical formulation of the present invention
  • the present invention is also directed to a suspension of particles of amorphous deferasirox according to the invention, in water or other drink suitable for human consumption wherein the amorphous deferasirox has a mean particle size of about 0.5 ⁇ m to about lO ⁇ m.
  • the present invention is further directed to a suspension of particles of amorphous deferasirox, wherein the deferasirox is substantially free of its acid addition salts and wherein the deferasirox has a mean particle size of about 0.5 ⁇ m to about lO ⁇ m, in water or other drink suitable for human consumption.
  • the present invention also provides a method of treating a disease prevented, ameliorated or eliminated by the administration of an iron chelating agent, in a subject in need thereof, such method comprises administering to the subject the suspension, according to the invention.
  • the present invention provides a method of treating iron overload following blood transfusion in a subject in need of such treatment, the method comprising administering to the subject the suspension of the present invention.
  • the amorphous forms of deferasirox can be characterized by the experimental method of FTIR, wherein a Perkin Elmer Spectrum, GX at a resolution of 4 cm "1 and 32 scan spectra was produced of each sample of amorphous deferasirox compressed with KBr into pellet (FIG.18 and FIG.19).
  • Deferasirox amorphous form I was prepared by melting a sample of deferasirox to around 260 °C and cooling quickly with an air stream to room temperature, within less than one minute.
  • Deferasirox amorphous form II is prepared by controlled cooling of a melted sample of deferasirox in a DSC instrument (QlOOO TA Instruments). 11 mg of deferasirox was placed in an open platinum sample pan under nitrogen pouring at a flow rate of 35 ml/min. The sample is equilibrated at 20 °C, heated with heating rate of 10 °C per min up to 270 °C (where the sample was in a melted state) isothermal heating was continued at 270 °C for 1 minute. The sample was then cooled at a rate of 30 °C/min to 20 °C, (the DSC was calibrated with indium).
  • Deferasirox amorphous form III was prepared by controlled cooling of a melted sample of deferasirox in a DSC instrument (QlOOO TA Instruments). 10 mg of deferasirox is placed in an open platinum sample pan under nitrogen pouring at a flow rate of 35 ml/min. The sample is equilibrated at 20 °C, heated with heating rate of 10 0C per min up to 270 °C (where the sample was in a melted state) isothermal heating was continued at 270 0 C for 1 minute. The sample was then cooled with a rate of 0.5 °C/min to 20 °C, (the DSC was calibrated with indium).
  • Deferasirox form IV is prepared by grinding of a (10 mg) sample of deferasirox in a ball mill FRITSCH Pulversette 7 at 800 rpm for 6 hours.
  • Granulate deferasirox with an aqueous dispersion of crospovidone and sodium lauryl sulfate Screen the dried granules through a 30 mesh (0.6 mm) sieve, and add all of the other substances, except magnesium stearate, and homogenize for 15 minutes. Add magnesium stearate, previously screened through a 30 mesh (0.6 mm) sieve, to the final blend and homogenize for another 5 minutes. The final blend is compressed into tablets.
  • the term "therapeutically effective amount” means an amount of deferasirox, according to the present invention, which is capable of preventing, ameliorating or eliminating a disease for which administration of deferasirox is indicated.
  • a “pharmaceutical formulation” refers to a medium useful for administering deferasirox, according to the present invention, to a subject in need thereof.
  • such formulations of the present invention can contain one or more pharmaceutically acceptable excipients.
  • “Pharmaceutically acceptable” refers to those compounds, materials, and/or compositions which are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other possible complications commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable it is further meant that the carrier, diluent or excipient is compatible with deferasirox, according to the invention, and not deleterious to a recipient thereof.
  • pharmaceutically acceptable excipients can be used with the present invention including those listed in the Handbook of Pharmaceutical Excipients, Pharmaceutical Press 4th Ed. (2003), and Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins, 21st ed. (2005), which are incorporated herein by reference in their entirety.
  • pharmaceutically acceptable excipients for use with the present invention include, but are not limited to, a carrier, a diluent, a binder, a disintegrant and combinations thereof, preferably wherein at least one pharmaceutically acceptable excipient is hygroscopic.
  • a “carrier” refers to a pharmaceutically acceptable excipient that is suitable for formulating with a pharmaceutical compound.
  • suitable carriers are, in particular, fillers such as sugars (preferably selected from lactose, sucrose, mannitol or sorbitol), cellulose preparations and/or calcium phosphates (preferably selected from tricalcium phosphate or calcium hydrogen phosphate).
  • a "diluent” refers to an inert substance that can be added to a composition to increase its bulk.
  • diluents suitable for use with the present invention include low substituted hydroxypropyl cellulose, pregelatinized starch, starch cellulose, lactose, dextrose, sucrose, dextrates, mannitol, maltodextrin, methylcellulose, microcrystalline cellulose, polyethylene glycol, calcium phosphate dibasic, calcium phosphate tribasic, calcium carbonate, calcium sulfate, and combinations thereof.
  • a “disintegrant” refers to refers to any exipient which decreases the disintegration time (accelerates the rate of disintegration) of a formulation.
  • Non- limiting examples of disintegrants can be selected from the group consisting of sodium starch glycolate, crosscarmellose sodium, crosslinked polyvinylpyrrolidone (crospovidone), agar or alginic acid or a salt thereof (such as sodium alginate) and low substituted hydroxypropylcellulose.
  • a "binder” refers to an excipient that can improve the cohesive qualities of a composition.
  • a binder can improve the compressibility of a composition (i.e., compactable binders can increase the cohesive properties of a composition upon compression).
  • binders for use with the present invention are polymers.
  • polymers for use as binders with the present invention are hydrophilic polymers.
  • a "hydrophilic polymer” refers to a polymeric material with an affinity for water, that is to say that a hydrophilic polymer can be hygroscopic in nature, wherein hygroscopic is defined as readily absorbing moisture.
  • hydrophilic polymers include polymers with polar or polarizable side groups, charged side groups, or combinations thereof.
  • binders include hydroxyethyl cellulose (e.g., available as NATROSOL ® 250 HX Pharm, Hercules Inc.
  • hydroxypropyl cellulose hydroxypropylmethyl cellulose
  • Hypromellose 2208 available as METHOCEL ® K3 Premium LV, The Dow Chemical Company, Midland, MI
  • hydroxypropylethyl cellulose sodium carboxymethylcellulose, carboxyethyl cellulose, powdered cellulose, methylcellulose, microcrystalline cellulose
  • polyethylene glycol polymers of alginic acid and salts thereof (e.g., "alginates,” such as sodium alginate, potassium alginate, and propane- 1,2-diol alginate), polyvinyl pyrrolidone (e.g., povidone), hydrophilic gums (e.g., guar gum, karaya gum, xanthan gum, and the like), homopolymers of acrylic acid cross-linked with an allyl ether, pentaerythritol, an allyl ether of sucrose, or an allyl ether of propylene (
  • sugar- coated tablet cores are provided with suitable, if desired enteric, coatings, using, inter alia, concentrated sugar solutions which, if desired, contain gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, coating solutions in suitable organic solvents or solvent mixtures or, for the preparation of enteric coatings, solutions of suitable cellulose preparations, such as acetylcellulose phthalate or hydroxypropylmethylcellulose phthalate, and colorants or pigments.
  • suitable enteric, coatings using, inter alia, concentrated sugar solutions which, if desired, contain gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, coating solutions in suitable organic solvents or solvent mixtures or, for the preparation of enteric coatings, solutions of suitable cellulose preparations, such as acetylcellulose phthalate or hydroxypropylmethylcellulose phthalate, and colorants or pigments.
  • the pharmaceutical formulations or pharmaceutical compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, intratracheal, intranasal, transdermal or rectal administration of deferasirox are administered to animals and humans in unit forms of administration, mixed with conventional pharmaceutical excipients, for the prophylaxis or treatment of disorders or diseases related to the accumulation of iron in the body.
  • the form of administration includes tablets, gelatin capsules, powders, granules and solutions or suspensions to be taken orally, forms for sublingual, buccal, intratracheal or intranasal administration, forms for subcutaneous, intramuscular or intravenous administration and forms for rectal administration.
  • a solid composition in the form of tablets is prepared deferasirox, according to the present invention, is mixed with a pharmaceutical vehicle such as lactose, crospovidone, microcrystalline cellulose, povidone, sodium lauryl sulphate, silica and magnesium stearate or the like.
  • a pharmaceutical vehicle such as lactose, crospovidone, microcrystalline cellulose, povidone, sodium lauryl sulphate, silica and magnesium stearate or the like.
  • the tablets can be coated with sucrose, a cellulose derivative or other appropriate substances, or treated so as to have a prolonged or delayed activity and so as to release a predetermined amount of active principle continuously.
  • the formulation is in the form of a dispersible tablet
  • the pharmaceutical formulation is a water-dispersible tablet.
  • Such water-dispersible tablets are formed by mixing deferasirox, according to the invention, with said carrier, diluent(s), and disintegrating agent(s), with additional dispersing agent(s), wetting agent(s), and/or suspending agent(s) such as polyvinylpyrrolidone, as well as with other optional or desirable excipients such as sweeteners, taste correctors or other flavoring agents.
  • excipients may have more than one function, for example certain disintegrating agents may also act as a dispersing agent.
  • Parenteral administration is effected using aqueous suspensions, isotonic saline solutions or sterile and injectable solutions which contain pharmacologically compatible dispersants and/or wetting agents, for example propylene glycol or butylene glycol.
  • the dispersible tablets are immersed in water or other suitable liquids or drink suitable for human consumption before administration to provide a suspension. Therefore, these tablets preferably satisfy the disintegration test, whereby the dispersible tablet should disintegrate within 3 minutes in 1 liter of water at 15 0 C to 25 °C.
  • the dispersible tablet preferably create a fineness of a dispersion which passes through a sieve screen with a nominal mesh aperture of 710 ⁇ m.
  • Dispersing agents are selected from the group comprising of crospovidone, sodium starch glycolate, croscarmellose sodium, starch and starch derivatives, alginates, cellulose and its derivatives, pharmaceutically acceptable gums, agar, chitin and chitosan or any combination thereof.
  • the dispersant is present in an amount of about 0.5% wt, in some embodiments the dispersant is present in an amount of about greater than 2.5% wt and in some embodiments the dispersant is present in an amount of about 5% wt.
  • the maximum amount of dispersant is about 20% wt, in some embodiments the maximum amount of dispersant is about 18% wt and in some embodiments the maximum amount of dispersant is about 15% wt.
  • a feature of the invention is a suspension of particles of deferasirox, according to the invention in water or other drink suitable for human consumption wherein the deferasirox, has a mean particle size of about 0.5 ⁇ m to about lO ⁇ m.
  • wetting agents are selected from the group comprising alkyl sulfate salts and sodium lauryl sulfate or any combination thereof, hi some embodiments a wetting agent is present in an amount of about 0.05% wt, in some embodiments a wetting agent is present in an amount of about 0.5% wt, in some embodiments a wetting agent is present in an amount of about 1% wt, in some embodiments a wetting agent is present in an amount of about 3% wt, in some embodiments a wetting agent is present in an amount of about 4% wt and in some embodiments a wetting agent is present in an amount of about 5% wt.
  • Suspending agents are selected from one or more of the following alginates, cellulose and its derivatives, pharmaceutically acceptable gums, agar, or chitosan.
  • a suspending agent is present in an amount of about 0.01% wt, in some embodiments a suspending agent is present in an amount of about greater than 0.05% wt and in some embodiments a suspending agent is present in an amount of about 0.1% wt.
  • the maximum amount of suspending agent is less than about 10% wt, less than about 7.5% wt and less than about 5% wt.
  • a dispersing agent may also act as a suspending agent. It is preferable for the performance of the dispersible tablet that at least one carrier, diluent or any other excipient is hygroscopic so to accelerate water intake providing rapid dispersion of the tablet.
  • deferasirox can optionally be used as a pharmaceutical formulation in the form of a powder, or in the form of granules. Controlling the particle size of the deferasirox enhances bioavailability and control during the manufacturing process. It has now been found that by bringing the particle size of the deferasirox forms of the present invention within a specified range, pharmaceutical formulations may be prepared which exhibit a consistent in vitro dissolution profile and in vivo bioavailability. In addition to bringing about these desired dissolution/bioavailability characteristics, the control of particle size to a preferred range has also resulted in significant improvements in manufacturing capabilities.
  • the deferasirox, of the pharmaceutical formulation has a mean particle size of about 0.1 ⁇ m to about 50 ⁇ m, in some embodiments of the current invention the deferasirox, of the pharmaceutical formulation has a mean particle size of about 0.5 ⁇ m to about 25 ⁇ m and in some embodiments of the current invention the deferasirox, according to the present invention, of the pharmaceutical formulation has a mean particle size of about l ⁇ m to about lO ⁇ m.
  • the deferasirox, of the pharmaceutical formulation has a D [90] of about 50 ⁇ m or less, in some embodiments of the current invention the deferasirox, according to the present invention, of the pharmaceutical formulation has a D [90] of about 25 ⁇ m or less and in some embodiments of the current invention the deferasirox, according to the present invention, of the pharmaceutical formulation has a D [90] of about 10 ⁇ m or less.
  • the deferasirox, of the pharmaceutical formulation has a D [50] of about 25 ⁇ m or less, in some embodiments of the current invention the deferasirox, according to the present invention, of the pharmaceutical formulation has a D [50] of about lO ⁇ m or less and in some embodiments of the current invention the deferasirox, according to the present invention, of the pharmaceutical formulation has a D[50] of about 5 ⁇ m or less.
  • the deferasirox, of the pharmaceutical formulation has a mean particle size of about 50 ⁇ m or less, in some embodiments of the current invention the deferasirox, according to the present invention, of the pharmaceutical formulation has a mean particle size of about 25 ⁇ m or less and in some embodiments of the current invention the deferasirox, according to the present invention, of the pharmaceutical formulation has a mean particle size of about 10 ⁇ m or less.
  • the particle size measurements of the deferasirox, according to the invention are mean particle size, which means the value D [4,3], the volume moment mean of the particles, D[90], the diameter of which 90% by weight of the particles are smaller than and D[50], the diameter of which 50% by weight of the particles are smaller than. All measurements are made by low angle laser light scattering (LALLS) as determined typically by a Malvern Mastersizer machine.
  • LALLS low angle laser light scattering
  • deferasirox according to the invention for use in therapy.
  • Deferasirox, according to the invention for use in a disease state prevented, ameliorated or eliminated by the administration of an iron chelating agent.
  • Deferasirox, according to the invention for use in treating iron overload following a blood transfusion.
  • the present invention further provides deferasirox, according to the invention, for use in the manufacture of a medicament for the treatment of a disease state prevented, ameliorated or eliminated by the administration of an iron chelating agent. More specifically, the present invention provides deferasirox, according to the invention, for use in the manufacture of a medicament for the treatment of iron overload following blood transfusion.
  • the present invention also provides a method of treating a disease state prevented, ameliorated or eliminated by the administration of an iron chelating agent, in a patient in need of such treatment, which method comprises administering to the patient a therapeutically effective amount of deferasirox, according to the invention. More specifically, the present invention provides a method of treating iron overload following blood transfusion in a patient in need of such treatment, which method comprises administering to the patient a therapeutically effective amount of deferasirox, according to the invention.
  • the dose of deferasirox can vary between about 10 mg per kg and about 30 mg per kg of body weight per day. Each unit dose can contain from about 100 to about 600 mg, preferably about 125 to about 500 mg of deferasirox in combination with a pharmaceutical carrier. These unit doses are preferably administered once a day.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des formulations pharmaceutiques comprenant une dose thérapeutiquement efficace d'une forme anhydre stable de déférasirox ainsi qu'un excipient pharmaceutiquement acceptable, le déférasirox étant sensiblement exempt de ses sels d'addition d'acide. La présente invention concerne également des procédés de préparation de cette forme stable, des procédés de préparation de ces formulations pharmaceutiques ainsi que de des méthodes d'utilisation desdites formulations pour traiter des affections chez un sujet ayant besoin d'un tel traitement. La présente invention concerne en outre de nouvelles formes polymorphes de déférasirox et de nouvelles formes amorphes de déférasirox, des procédés de préparation de ces formes, des compositions pharmaceutiques les contenant, leurs utilisations thérapeutiques ainsi que des méthodes de traitement faisant appel à celles-ci.
PCT/GB2008/002572 2007-07-27 2008-07-25 Nouvelles formes de déférasirox WO2009016359A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US93513407P 2007-07-27 2007-07-27
US60/935,134 2007-07-27
US93548207P 2007-08-15 2007-08-15
US60/935,482 2007-08-15
US96028507P 2007-09-24 2007-09-24
US60/960,285 2007-09-24

Publications (1)

Publication Number Publication Date
WO2009016359A1 true WO2009016359A1 (fr) 2009-02-05

Family

ID=40044050

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/002572 WO2009016359A1 (fr) 2007-07-27 2008-07-25 Nouvelles formes de déférasirox

Country Status (1)

Country Link
WO (1) WO2009016359A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2062572A1 (fr) * 2007-11-19 2009-05-27 Teva Pharmaceutical Industries Ltd. Compositions pharmaceutiques
WO2009106824A2 (fr) * 2008-02-25 2009-09-03 Cipla Limited Formulations pharmaceutiques
WO2011070560A1 (fr) 2009-12-07 2011-06-16 Mapi Pharma Hk Limited Procédés pour la préparation du déférasirox, et polymorphes de déférasirox
WO2012003987A1 (fr) * 2010-07-08 2012-01-12 Ratiopharm Gmbh Forme posologique orale de déférasirox
WO2012042224A3 (fr) * 2010-10-01 2012-08-09 Cipla Limited Composition pharmaceutique
WO2014181108A1 (fr) * 2013-05-10 2014-11-13 Cipla Limited Composition pharmaceutique à faible dosage
WO2017022997A1 (fr) * 2015-07-31 2017-02-09 건일제약 주식회사 Poudre contenant du déférasirox et procédé de préparation correspondant
EP3481390A4 (fr) * 2016-07-05 2020-03-04 Jubilant Generics Limited Composition pharmaceutique à libération immédiate d'agents chélateurs du fer
EP4052698A1 (fr) 2021-03-05 2022-09-07 Sanovel Ilac Sanayi Ve Ticaret A.S. Comprimé pelliculé comprenant du déférasirox

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997049395A1 (fr) * 1996-06-25 1997-12-31 Novartis-Erfindungen Verwaltungsgesellschaft M.B.H. 3,5-diphenyl-1,2,4-triazoles substitues et leur utilisation comme chelateurs de metaux pharmaceutiques
WO2004035026A1 (fr) * 2002-10-15 2004-04-29 Novartis Ag Comprimes solubles de deferasirox
WO2008065123A2 (fr) * 2006-11-29 2008-06-05 Novartis Ag Sels et formes cristallines de l'acide 4-[3,5-bis(2-hydroxyphényl)-[1,2,4]triazol-1-yl]benzoïque
WO2008094617A2 (fr) * 2007-01-29 2008-08-07 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Formes cristallines de déférasirox

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997049395A1 (fr) * 1996-06-25 1997-12-31 Novartis-Erfindungen Verwaltungsgesellschaft M.B.H. 3,5-diphenyl-1,2,4-triazoles substitues et leur utilisation comme chelateurs de metaux pharmaceutiques
US20030069273A1 (en) * 1996-06-25 2003-04-10 Rene Lattmann Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
WO2004035026A1 (fr) * 2002-10-15 2004-04-29 Novartis Ag Comprimes solubles de deferasirox
WO2008065123A2 (fr) * 2006-11-29 2008-06-05 Novartis Ag Sels et formes cristallines de l'acide 4-[3,5-bis(2-hydroxyphényl)-[1,2,4]triazol-1-yl]benzoïque
WO2008094617A2 (fr) * 2007-01-29 2008-08-07 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Formes cristallines de déférasirox

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Crystalline (4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid and process for preparation thereof", IP.COM PRIOR ART DATABASE, no. ipcom000146862D, 26 February 2007 (2007-02-26), XP002506935, Retrieved from the Internet <URL:www.ip.com> [retrieved on 20081204] *
VAN ORDEN HEIDI E ET AL: "Deferasirox - An oral agent for chronic iron overload", ANNALS OF PHARMACOTHERAPY,, vol. 40, no. 6, 1 June 2006 (2006-06-01), pages 1110 - 1117, XP009109627, ISSN: 1060-0280 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2062572A1 (fr) * 2007-11-19 2009-05-27 Teva Pharmaceutical Industries Ltd. Compositions pharmaceutiques
WO2009106824A2 (fr) * 2008-02-25 2009-09-03 Cipla Limited Formulations pharmaceutiques
WO2009106824A3 (fr) * 2008-02-25 2010-05-14 Cipla Limited Formulations pharmaceutiques
WO2011070560A1 (fr) 2009-12-07 2011-06-16 Mapi Pharma Hk Limited Procédés pour la préparation du déférasirox, et polymorphes de déférasirox
EP2509423A1 (fr) * 2009-12-07 2012-10-17 Mapi Pharma Limited Procédés pour la préparation du déférasirox, et polymorphes de déférasirox
US8772503B2 (en) 2009-12-07 2014-07-08 Mapi Pharma Ltd. Processes for the preparation of deferasirox, and deferasirox polymorphs
EP2509423A4 (fr) * 2009-12-07 2013-07-31 Mapi Pharma Ltd Procédés pour la préparation du déférasirox, et polymorphes de déférasirox
WO2012003987A1 (fr) * 2010-07-08 2012-01-12 Ratiopharm Gmbh Forme posologique orale de déférasirox
EP2929877A1 (fr) * 2010-07-08 2015-10-14 ratiopharm GmbH Forme posologique orale de déférasirox
US8703203B2 (en) 2010-07-08 2014-04-22 Ratiopharm Gmbh Oral dosage form of deferasirox
US20140147503A1 (en) * 2010-10-01 2014-05-29 Cipla Limited Pharmaceutical Composition Comprising Deferasirox
CN103209687A (zh) * 2010-10-01 2013-07-17 希普拉有限公司 包含地拉罗司的药物组合物
AU2011309872B2 (en) * 2010-10-01 2014-09-04 Cipla Limited Pharmaceutical composition comprising deferasirox
WO2012042224A3 (fr) * 2010-10-01 2012-08-09 Cipla Limited Composition pharmaceutique
AP3578A (en) * 2010-10-01 2016-02-08 Cipla Ltd Pharmaceutical composition comprising deferasirox
WO2014181108A1 (fr) * 2013-05-10 2014-11-13 Cipla Limited Composition pharmaceutique à faible dosage
CN105377256A (zh) * 2013-05-10 2016-03-02 奇普拉股份有限公司 低剂量药物组合物
WO2017022997A1 (fr) * 2015-07-31 2017-02-09 건일제약 주식회사 Poudre contenant du déférasirox et procédé de préparation correspondant
RU2695616C1 (ru) * 2015-07-31 2019-07-24 Кухниль Фарм. Ко., Лтд. Порошок, содержащий деферазирокс, и способ его приготовления
EP3481390A4 (fr) * 2016-07-05 2020-03-04 Jubilant Generics Limited Composition pharmaceutique à libération immédiate d'agents chélateurs du fer
EP4052698A1 (fr) 2021-03-05 2022-09-07 Sanovel Ilac Sanayi Ve Ticaret A.S. Comprimé pelliculé comprenant du déférasirox

Similar Documents

Publication Publication Date Title
WO2009016359A1 (fr) Nouvelles formes de déférasirox
TW202334115A (zh) N-(4-(4-(環丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺醯胺之結晶型
JP2014530805A (ja) アジルサルタンの結晶形並びにその製造及び使用
JP2020513023A (ja) ルマテペロンｐ−トシラートの非晶質形態および固体分散体
EP2897943A1 (fr) Nouvelle forme cristalline de bromhydrate de vortioxétine
JP2010513264A (ja) アジミライドジヒドロクロリド組成物
KR20200118098A (ko) 약제학적 화합물, 이의 염, 이의 제형, 그리고 이의 제조 방법 및 사용 방법
AU2002338726B9 (en) Pseudopolymorphic forms of carvedilol
US20170226119A1 (en) Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof
AU2002338726A1 (en) Pseudopolymorphic forms of carvedilol
US20160115165A1 (en) Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
US9464086B2 (en) Crystalline forms of N,N-dicyclopropyl-4-(1,5-dimethyl-1 H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-D]pyrrolo[2,3-B]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
US9598413B2 (en) Crystalline form of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-D]pyrrolo[2,3-B]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
US20160090385A1 (en) Crystalline forms of n,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboximide for the treatment of myeloproliferative disorders
US20040038985A1 (en) Crystal forms of 1- [6-chloro-5-(trifluoromethly) -2-pyridinyl] piperazine hydrochloride
US11795180B2 (en) Formulation of a pan-JAK inhibitor
EP3912971A1 (fr) Polymorphe d&#39;inhibiteur de la cholinestérase et utilisation associée
JP2023533874A (ja) Ｐｎ６０４７の塩酸塩の多形体
CN116354956A (zh) 维利西呱晶型及其制备方法
KR20110115607A (ko) 6-옥소-6,7,8,9,10,11-헥사히드로시클로헵타(ｃ)크로멘-3-일 술파메이트 및 그의 다형체를 함유하는 고체 제약 조성물
KR20130010132A (ko) 모다피닐 조성물
KR20060123613A (ko) 모다피닐 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08776078

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08776078

Country of ref document: EP

Kind code of ref document: A1